Reporter Virus Particles in Takeda’s Zika and dengue vaccine development
When Takeda needed a safe, high-throughput assay for testing large numbers of vaccine sera, they turned to Reporter Virus Particles (RVPs). Read the case study to learn how this leading vaccine developer set up and validated their neutralization assays, and how the assays helped advance the vaccines through clinical trials.
- High correlation between PRNT and RVP neutralization assays
- Using RVP assays in clinical studies
- RVP stability and assay reproducibility
- Links to primary research articles